Baird Cuts Price target on Opower (OPWR) to $9; Says Low Guide may Pressure the Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Pacific Crest Downgrades Opower (OPWR) to Sector Weight
March 1, 2016 8:01 AM ESTPacific Crest downgraded Opower (NYSE: OPWR) from Overweight to Sector Weight.
For an analyst ratings summary and ratings history on Opower click here. For more ratings news on Opower click here.
Shares of Opower closed at $8.27 yesterday.
... MoreWilliam Blair Downgrades Opower (OPWR) to Market Perform
March 1, 2016 7:23 AM ESTWilliam Blair downgraded Opower (NYSE: OPWR) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Opower click here. For more ratings news on Opower click here.
Shares of Opower closed at $8.27 yesterday.
... MoreAfter-Hours Stock Movers 02/29: (CRC) (APEI) (CECO) Higher; (RMTI) (DPLO) (OPWR) Lower (more...)
February 29, 2016 6:07 PM ESTRockwell Medical Technologies (NASDAQ: RMTI) 27.6% LOWER; reported Q4 EPS of ($0.12), $0.14 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $14.1 million versus the consensus estimate of $19.98 million.
Diplomat Pharmacy (NYSE: DPLO) 25.6% LOWER; reported Q4 EPS of $0.21, $0.01 better than the analyst estimate of $0.20. Revenue for the quarter came in at $987 million versus the consensus estimate of $969.7 million. GUIDANCE: Diplomat Pharmacy sees FY2016 EPS of $0.84-$0.89, versus the consensus of $1.00. Diplomat Pharmacy sees FY2016 revenue of $4.3-4.6... More
Opower (OPWR) Reports In-Line Q4 EPS, Offers Q1 & FY Guidance
February 29, 2016 4:53 PM ESTOpower (NYSE: OPWR) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $39.97 million.
GUIDANCE:
Opower sees FY2016 EPS of ($0.36)-($0.45), versus the consensus of ($0.40). Opower sees... More
Trading Radar for 2/29: Curis (CRIS), Lumber Liquidators (LL), Netlist (NLST), TASER Int'l (TASR) Report
February 26, 2016 3:19 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
3D Systems (NYSE: DDD) - consensus EPS $0.03
AMC Entertainment (NYSE: AMC) - consensus EPS $0.40
Acadia Pharma (Nasdaq: ACAD) - consensus loss $0.38
Altisource Residential (NYSE: RESI) - consensus EPS $0.18
Ares Management (Nasdaq: ARES) - consensus EPS $0.29
Arqule (Nasdaq: ARQL) - consensus loss... More
